Wallace M/LinkedIn
Jan 3, 2026, 14:08
Wallace M Shares a SWOT Analysis of Aqvesme’s FDA Approval
Wallace M, CEO and Founder of i3consult.com, shared on LinkedIn:
”FDA APPROVAL UPDATE: Aqvesme™ (mitapivat) for Thalassemia‑Related Anemia
The FDA approval of Aqvesme™ introduces the first oral, disease‑modifying therapy for anemia in adults with alpha‑ or beta‑thalassemia.
Our latest SWOT analysis explores the clinical significance and strategic implications of this milestone.
Read the full analysis.”
Stay updated with Hemostasis Today.
-
Jan 4, 2026, 17:02Oğuzhan Işılay on Stabilizing Human Blood Clotting Factor VIII
-
Jan 4, 2026, 16:48Sleep Apnea: Full Breakdown from John Chuback
-
Jan 4, 2026, 16:36Edwin Ofori Atta on Permissive Hypertension For Ischemic Stroke
-
Jan 4, 2026, 16:27Nasrin Haghani on The Milli-Spinners: Breakthrough Technology Transforming Stroke Clot Removal
-
Jan 4, 2026, 16:10Godfrey Gandawa on Neuroplasticity in Stroke Rehabilitation
-
Jan 4, 2026, 14:53What Do Blood and Plasma Donors Think About Biobanking? A New Study Reveals Their Attitudes
-
Jan 4, 2026, 14:51First Results from the International BPDCN Registry: Data from 36 Patients Across 12 Countries
-
Jan 4, 2026, 14:51Shreya Agrawal: Top 5 Practical Hematology Lessons from 2025 – Mild Cytopenias are Rarely “Incidental” and More
-
Jan 4, 2026, 14:46We Analyzed Data From the Start of the COVID-19 Pandemic to 2024 – What Did We find?